Evidence map›Paper›PMID 32916600›Full record

ArticleMolecular therapy. Nucleic acids2020

N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool.

Joséphine Briand, Aurélien A Sérandour, Arulraj Nadaradjane, Gwenola Bougras-Cartron, Dominique Heymann, Benjamin Ory, François M Vallette, Pierre-François Cartron

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Joséphine BriandCRCINA, INSERM, Université de Nantes, Nantes, France; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Nantes, France; EpiSAVMEN Network (Région Pays de la Loire), Nantes, France.
Aurélien A SérandourCRCINA, INSERM, Université de Nantes, Nantes, France; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Nantes, France; EpiSAVMEN Network (Région Pays de la Loire), Nantes, France; Ecole Centrale Nantes, Nantes, France.
Arulraj NadaradjaneCRCINA, INSERM, Université de Nantes, Nantes, France; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Nantes, France; EpiSAVMEN Network (Région Pays de la Loire), Nantes, France; LabEX IGO, Université de Nantes, Nantes, France.
Gwenola Bougras-CartronCRCINA, INSERM, Université de Nantes, Nantes, France; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Nantes, France; EpiSAVMEN Network (Région Pays de la Loire), Nantes, France.
Dominique HeymannCRCINA, INSERM, Université de Nantes, Nantes, France; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Benjamin OryCancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Nantes, France; EpiSAVMEN Network (Région Pays de la Loire), Nantes, France; INSERM, U1238, Université de Nantes, Nantes, France.
François M ValletteCRCINA, INSERM, Université de Nantes, Nantes, France; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France; LabEX IGO, Université de Nantes, Nantes, France.
Pierre-François CartronCRCINA, INSERM, Université de Nantes, Nantes, France; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Nantes, France; EpiSAVMEN Network (Région Pays de la Loire), Nantes, France; LabEX IGO, Université de Nantes, Nantes, France. Electronic address: pierre-francois.cartron@inserm.fr.
Inserm · FRÉcole Centrale de Nantes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs or miRs) play crucial roles in biological and pathological processes. Some miRNAs also appear as promising biomarkers and therapeutic tools. However, the epitranscriptomic regulation of miRNAs is not yet fully elucidated in all of their fields of application. We report that adenosine methylation of miR-200b-3p inhibits its repressive function toward its mRNA targets such as XIAP by blocking the formation of the miRNA/3' UTR

Indexed as

adenosine methylationbiomarkerglioblastomamiRNA methylationprodrug

Identifiers

PMID32916600
PMCPMC7490450
OpenAlexW3049608521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.